Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

被引：0
|
作者：
Christian Lehmann
Thomas Friess
Fabian Birzele
Anna Kiialainen
Markus Dangl
机构：
[1] Roche Pharma Research & Early Development,
[2] Roche Innovation Center Munich,undefined
[3] Roche Diagnostics GmbH,undefined
[4] Roche Pharma Research & Early Development,undefined
[5] Roche Innovation Center Basel,undefined
[6] F-Hoffmann-La Roche Ltd,undefined
[7] Present address: Medigene Immunotherapies GmbH,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
BCL-2; MDM2; AML; Cell cycle kinetics; Apoptosis; Idasanutlin; Venetoclax; p53; MCL-1; Synergism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Lehmann, Christian
    Friess, Thomas
    Birzele, Fabian
    Kiialainen, Anna
    Dangl, Markus
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] The MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    Gu, Lubing
    Zhu, Ningxi
    Findley, Harry W.
    Zhou, Muxiang
    BLOOD, 2007, 110 (11) : 137B - 137B
  • [3] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    Gu, L.
    Zhu, N.
    Findley, H. W.
    Zhou, M.
    LEUKEMIA, 2008, 22 (04) : 730 - 739
  • [4] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    L Gu
    N Zhu
    H W Findley
    M Zhou
    Leukemia, 2008, 22 : 730 - 739
  • [5] The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models
    Herting, Frank
    Friess, Thomas
    Umana, Pablo
    Steven, Middleton
    Klein, Christian
    BLOOD, 2016, 128 (22)
  • [6] The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors
    Spiegelberg, Diana
    Mortensen, Anja C.
    Lundsten, Sara
    Brown, Christopher J.
    Lane, David P.
    Nestor, Marika
    CANCER RESEARCH, 2018, 78 (17) : 5084 - 5093
  • [7] Synergistic Anti-Leukemic Activity with Combination of FLT3 Inhibitor Quizartinib and MDM2 Inhibitor Milademetan in FLT3-ITD Mutant/p53 Wild-Type Acute Myeloid Leukemia Models
    Andreeff, Michael
    Zhang, Weiguo
    Kumar, Prasanna
    Zernovak, Oleg
    Daver, Naval G.
    Isoyama, Takeshi
    Iwanaga, Kouichi
    Togashi, Noriko
    Seki, Takahiko
    BLOOD, 2018, 132
  • [8] Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML)
    Nimmagadda, Subbaiah Chary
    Patnana, Pradeep Kumar
    Budde, Paulina Marie
    Ahmed, Helal
    Covey, Todd
    Krejsa, Cecile
    Rothbaum, Wayne
    Von Bubnoff, Nikolas
    Khandanpour, Cyrus
    BLOOD, 2023, 142
  • [9] MDM2 INHIBITOR SYNERGY WITH BCL-XL INHIBITION FOR P53 WILD TYPE GLIOBLASTOMA
    Rahman, Masum
    Olson, Ian E.
    Saber, Rehan
    Carlstrom, Lucas P.
    Jhang, Jibo
    Brown, Desmond
    Rajani, Karishma
    Sarkaria, Jann
    Parney, Ian
    Burns, Terry C.
    NEURO-ONCOLOGY, 2020, 22 : 18 - 18
  • [10] p53 mutations induced by the MDM2 inhibitor nutlin-3 in p53 wild-type neuroblastoma cells
    Michaelis, M.
    Wass, M.
    Cinatl, J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S72 - S72
12345